Cornerstone BioPharma, Inc.

2000 Regency Parkway, Suite 255
Cary
North Carolina
27511
United States

Tel: 888-466-6503 or 888-466-6503

Website: http://www.cornerstonebiopharma.com/

About Cornerstone BioPharma, Inc.

Cornerstone BioPharma, Inc., located next to North Carolina’s Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the pain, anti-infective, and respiratory markets. The privately held company owns the rights to a pain product line, three respiratory product lines, and co-promotes the Suprax® antibiotic. Cornerstone is actively engaged in the licensing of additional prescription products in niche markets through acquisitions and strategic partnerships.
For more information, please visit: www.cornerstonebiopharama.com
Last Updated: 03-14-05

8 articles about Cornerstone BioPharma, Inc.

Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

8/3/2022

Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful completion of a Phase 1b clinical trial of CPI-613® (devimistat) in combination with gemcitabine and cisplatin for the treatment of advanced unresectable biliary tract cancer.
Stipulation of Dismissal of Claims by Plaintiff Cornerstone BioPharma, Inc.

7/11/2013
Cornerstone BioPharma, Inc. Announces Completion of Merger with Critical Therapeutics

11/3/2008
Critical Therapeutics, Inc. Announces Stockholder Approvals Related to Merger with Cornerstone BioPharma, Inc. and 10-to-1 Reverse Stock Split

10/31/2008
Critical Therapeutics, Inc. Announces Effectiveness Of Registration Statement For The Proposed Merger With Cornerstone BioPharma, Inc.

10/6/2008
Cornerstone BioPharma, Inc. Welcomes David Price as CFO Price to Help Lead Company Through Transition, Growth

8/21/2008
Critical Therapeutics, Inc. Signs Definitive Agreement to Merge with Cornerstone BioPharma, Inc.

5/2/2008
Lupin Ltd. And Cornerstone BioPharma, Inc. End Drug Deal

12/27/2006